George Mason University researchers developed an HIV-like virus particle called HIV Rev-dependent lentiviral vector, which could potentially end the need for lifelong HIV medications.

George Mason University researchers led by Yuntao Wu developed an HIV-like virus particle called HIV Rev-dependent lentiviral vector, published in Gene Therapy journal. This breakthrough proof-of-concept study suggests that the virus particle could potentially end the need for lifelong HIV medications. The virus uses an HIV protein, Rev, to selectively target and activate therapeutic genes in infected cells.

July 24, 2024
3 Articles